Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bausch Health (BHC) Q1 Earnings Expected to Decline

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 podium presentations and four poster presentations related to the company's products and pipeline programs during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which will take place in San Diego from May 5-8, 2023. The posters and present.

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the “Annual Meeting”) held on April 24, 2023. The detailed results of the vote for the election of directors are set out below: Name   For   Against   Broker Non-Votes Nathalie Bernier   344,.

Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

Program Seeks to Increase the Number of People Screened to Help Prevent Colorectal Cancer Diagnoses in Philadelphia LAVAL, QC / ACCESSWIRE / April 24, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, today announced a partnership with the Colorectal Cancer Alliance (Alliance), the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase awareness and access to preventative colorectal screenings in medically underserved communities. This May, the Alliance is launching a colorectal cancer screening and prevention initiative in Philadelphia with a focus on the communities facing the greatest disparities in health outcomes.

Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System. StableVisc and TotalVisc provide eye surgeons with new options for dual-action protection during cataract surgery. "OVDs are critical to surgeons' success when performing cat.

Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of eight scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in New Orleans from April 23-27, 2023.

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 65.8 million units, or 397,194 pounds, of used contact lenses, eye care and lens care materials, which is equivalent to the weight of three commercial-sized airplanes.

Bausch + Lomb Reports More Than 65 Million Units of Contact Lens, Eye Care and Lens Care Materials Recycled Through ONE by ONE and Biotrue® Eye Care Recycling Programs

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2023 financial results on Wednesday, May 3, 2023. Bausch + Lomb will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update.

Bausch + Lomb Will Release First-Quarter 2023 Financial Results on May 3

LAVAL, QC / ACCESSWIRE / April 13, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce First-Quarter 2023 Results on May 4

Salix Pharmaceuticals Releases Third Annual Patient Perspectives Report LAVAL, QC / ACCESSWIRE / April 4, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome (IBS) or chronic idiopathic constipation (CIC). The report, Patient Perspectives: Impacts of Living with IBS, offers a current understanding of the behaviors and experiences of the IBS and CIC patient population, including insights on diagnosis, barriers to provider discussions, and symptom management.

New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider

VAUGHAN, Ontario & HEIDELBERG, Germany--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in class ocular therapeutics, today announced that American Journal of Ophthalmology has published results from MOJAVE, the second pivotal Phase 3 trial for NOV03 (perfluorohexyloctane).

Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in American Journal of Ophthalmology

LAVAL, QC / ACCESSWIRE / March 1, 2023 / Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) today announced that Richard De Schutter and Dr. Argeris Karabelas are retiring from the Company's Board of Directors, effective as of the upcoming 2023 annual meeting of shareholders of the Company. Following the retirements of Mr.

Bausch Health Announces Changes to its Board of Directors

Bausch + Lomb Corporation recently appointed a new high-profile CEO in Brent Saunders. Bausch Health Companies Inc. has hit the internal metrics necessary to justify spinning off more Bausch + Lomb shares.

Bausch Health: Full Bausch + Lomb Spin-Off Finally Seems Close

Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.

Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up

Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

Bausch Health Companies Inc. (NYSE:BHC ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Thomas Appio - Chief Executive Officer Tom Vadaketh - Chief Financial Officer Conference Call Participants Georgi Yordanov - Cowen and Company Douglas Miehm - RBC Capital Markets Glen Santangelo - Jefferies David Amsellem - Piper Sandler Jason Gerberry - Bank of America Gary Nachman - BMO Umer Raffat - Evercore ISI Operator Good morning, and welcome to Bausch Health's Fourth Quarter 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode.

Bausch Health Companies Inc. (BHC) Q4 2022 Earnings Call Transcript

Fourth-Quarter revenues of $2.2 billion, flat reported, up 4% organic1 Full-Year revenues of $8.1 billion, down 4% reported, up 2% organic1 Unrestricted B+L from BHC covenants Reduced debt by $464 million in the fourth quarter Provides 2023 guidance for Bausch Health (excl. B+L) LAVAL, QC / ACCESSWIRE / February 23, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced its fourth-quarter and full-year 2022 financial results.

Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results

Bausch + Lomb Corp

Bausch + Lomb Corp. BLCO, -2.01% said Wednesday it had a loss of $1 million, or breakeven on a per-share basis, for the fourth quarter, after earnings of $51 million, or 15 cents a share, in the year-earlier period. The company, which went public in May when it was spun out of Bausch Health, said adjusted per-share earnings came to 23 cents, a penny ahead of the 22 cent FactSet consensus.

Bausch + Lomb beats Q4 profit and revenue estimates

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Bausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?

Bausch + Lomb Corp. BLCO, +1.31% said Wednesday it has named Brent Saunders as chief executive and chair effective March 6. Saunders, who will return to the company he headed from 2010 to 2013, will replace Joseph Papa, who is stepping down.

Bausch + Lomb names ex-CEO Brent Saunders as CEO, replacing Joseph Papa

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer (“CEO”) and chair of the Board of Directors (“Board”) of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director.

Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

Salix to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESSWIRE / February 13, 2023 / Bausch Health Companies Inc. (NYSE/TSX:BHC) today announced the opening of the 2023 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.

Salix Announces 2023 Gastrointestinal Health Scholars Program

Crown Hlds

CVR Energy

FirstEnergy

Herc Hlds

Icahn Enterprises

Newell Brands

Southwest Gas Hlds

Xerox

Carl Icahn is one of the most successful investors of all time and is the founder and controlling shareholder of Icahn Enterprises.

These Are the Top 10 Holdings of Carl Icahn

LAVAL, QC / ACCESSWIRE / February 1, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23

VAUGHAN, Ontario & TAMPERE, Finland--( BUSINESS WIRE )--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Modulight Corporation (“Modulight”), a biomedical laser company, today announced that the U.S. Food and Drug Administration (FDA) has approved the ML6710i photodynamic laser for equivalent use with Bausch + Lomb's VISUDYNE® (verteporfin for injection) photodynamic therapy (PDT) for the treatment of patients with predominantly classic subfoveal choroidal neovascularization, or the creation of abnormal choroidal blood vessels, due to Age-related Macular Degeneration (AMD).1 ML6710i is expected to be available for eye care professionals during the first half of 2023.

News for Bausch Health Companies Inc Stock (BHC)